Multiple sclerosis. New therapeutic strategies in the experimental stage [Multiple Sklerose. Neue therapeutische Strategien im experimentellen Stadium]

被引:0
|
作者
Zipp F. [1 ,2 ]
Sommer N. [1 ]
Rösener M. [1 ]
Dichgans J. [1 ]
Martin R. [1 ]
机构
[1] Neurologische Universitätsklinik, Tübingen
[2] Neurologische Klinik, Eberhard-Karls-Universität Tübingen, D-72076 Tübingen
关键词
immunopathogenesis; multiple sclerosis; therapy;
D O I
10.1007/s001150050103
中图分类号
学科分类号
摘要
Extensive research in the field of multiple sclerosis (MS) has lead to a preliminary pathogenetic concept without solving the etiopathogenesis. According to animal experiments and human in vitro studies MS is a T cell-mediated autoimmune disease. Experimental therapeutical strategies are aiming at the inhibition of T cell activation, transmigration through the blood brain barrier and local inflammation and demyelination. Several substances are already being tested in clinical studies with magnetic resonance imaging as a tool to quantify inflammatory lesions and to shorten the study course. This review will give a summary about actual experimental therapies resulting from the current pathogenetic concept.
引用
收藏
页码:94 / 101
页数:7
相关论文
共 35 条
  • [31] Neuroglial components of brain lesions may provide new therapeutic strategies for multiple sclerosis
    Khanghahi, Akram Mokhtarzadeh
    Rayatpour, Atefeh
    Baharvand, Hossein
    Javan, Mohammad
    NEUROLOGICAL SCIENCES, 2023, 44 (11) : 3795 - 3807
  • [32] Use of peptide-fluorophore conjugates to asses putative targeting to glia of peptide-drug hybrid molecules as a new therapeutic approach for Multiple Sclerosis.
    Josa-Prado, F.
    Tosat-Bitrian, C.
    Prieto-Mauricio, I.
    Gutierrez-Jimenez, O.
    Martinez, A.
    Palomo, V.
    de Castro, F.
    GLIA, 2021, 69 : E390 - E391
  • [33] Antegren (Natalizumab): A new therapeutic approach for the treatment of multiple sclerosis [Antegren (Natalizumab): Ein viel versprechender neuer ansatz für die therapie der multiplen sklerose]
    Kümpfel T.
    Heydari N.
    Hohlfeld R.
    Der Nervenarzt, 2002, 73 (6) : 552 - 555
  • [34] A Cyclophilin D Inhibitor (Debio 025) Protects Axons in Experimental Autoimmune Encephlomyelitis: A New Therapeutic Target for Neuroprotecion in Multiple Sclerosis
    Bourdette, Dennis
    Marracci, Gail
    Chaudhary, Priya
    Dumont, Jean-Maurice
    Vuagniaux, Gregoire
    Forte, Michael
    NEUROLOGY, 2010, 74 (09) : A564 - A564
  • [35] Pegylated interferon beta 1a: A new therapy option for treatment of relapsing-remitting multiple sclerosis [Pegyliertes Interferon-beta 1a: Eine neue Therapieoption zur Behandlung der schubförmigen multiplen Sklerose]
    Leussink V.I.
    Warnke C.
    Tackenberg B.
    Wiendl H.
    Kieseier B.C.
    Der Nervenarzt, 2015, 86 (4) : 483 - 490